Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

Cytochroma Inc.

Cytochroma is a clinical-stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD).

Investment year: 2002
Industry sector: Biotechnology
Region: Ontario
Website
Follow Cytochroma Inc.
BDC Venture Capital Partner

Ela Borenstein

Program Director